Clinical Effects of Serenoa Repens(Permixon) on Chronic Prostatitis / 대한비뇨기과학회지
Korean Journal of Urology
;
: 869-873, 1990.
Artigo
em Coreano
| WPRIM
| ID: wpr-37978
ABSTRACT
Chronic prostatitis has various symptoms and many problems in management. Recently a lipidosterolic extract of Serenoa Repens, Permixon has been reported to reveal potential antiandrogenic and anti inflammatory activities on prostate. Then we used Permixon on chronic prostatitis and following results were obtained. Permixon is administered orally in dose of 160mg., b.i.d. for 60 days in 31 cases of chronic prostatitis in 1st group, Permixon 160mg, with Cipro-floxacin 500mg, b.i.d. in 35 cases in 2nd group and Placebo 2 tablets, b.i.d. in 30 cases in 3rd group. In 1st group 36 cases(77.4%) were improved, 29 cases(82.8%) in 2nd group and 7 cases (23.3 %) of 3rd group were improved. Permixon is an effective drug in chronic prostatitis and there was no changes in laboratory findings and negligible side effects were noticed
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Próstata
/
Prostatite
/
Comprimidos
/
Serenoa
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Coreano
Revista:
Korean Journal of Urology
Ano de publicação:
1990
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS